Market Cap | 14.19B | P/E | 23.36 | EPS this Y | -5.70% | Ern Qtrly Grth | - |
Income | 360.2M | Forward P/E | 17.09 | EPS next Y | 21.00% | 50D Avg Chg | 2.00% |
Sales | 6.83B | PEG | 3.68 | EPS past 5Y | 9.75% | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 2.83 | EPS next 5Y | 6.90% | 52W High Chg | -28.00% |
Recommedations | 2.20 | Quick Ratio | 0.97 | Shares Outstanding | 679.84M | 52W Low Chg | 17.00% |
Insider Own | 1.25% | ROA | 3.67% | Shares Float | 676.88M | Beta | 1.33 |
Inst Own | 98.26% | ROE | 6.90% | Shares Shorted/Prior | 35.21M/36.39M | Price | 21.02 |
Gross Margin | 33.71% | Profit Margin | 5.28% | Avg. Volume | 6,115,253 | Target Price | 27.95 |
Oper. Margin | 10.36% | Earnings Date | Oct 25 | Volume | 5,186,418 | Change | 0.62% |
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
RBC Capital | Outperform | Sep 26, 24 |
Wells Fargo | Overweight | Aug 27, 24 |
TD Cowen | Buy | Jul 29, 24 |
Morgan Stanley | Overweight | Jul 29, 24 |
Barclays | Overweight | Jul 29, 24 |
RBC Capital | Outperform | Jul 29, 24 |
Stifel | Buy | Jul 29, 24 |
Baird | Outperform | Jul 29, 24 |
RBC Capital | Outperform | Jul 15, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Couturier Christophe | EVP, AMEA EVP, AMEA | Apr 11 | Sell | 21.18 | 1,498 | 31,728 | 98,650 | 04/13/23 |
Couturier Christophe | EVP, AMEA EVP, AMEA | Feb 23 | Sell | 24.24 | 3,078 | 74,611 | 94,370 | 02/27/23 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | Jan 31 | Sell | 25.06 | 11,339 | 284,155 | 102,385 | 02/02/23 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | May 20 | Sell | 31.27 | 19,603 | 612,986 | 96,935 | 05/23/22 |
Vanderhaegen Frederic | EVP, Americas & Euro.. EVP, Americas & Europe | May 23 | Sell | 31.61 | 39,000 | 1,232,790 | 126,764 | 05/23/22 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | Mar 01 | Sell | 34.47 | 2,027 | 69,871 | 136,221 | 03/02/22 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | Feb 23 | Sell | 33.79 | 3,059 | 103,364 | 125,181 | 02/25/22 |
GUPTA RAJIV | Director Director | May 26 | Sell | 31.66 | 337,571 | 10,687,498 | 506,218 | 05/26/21 |
Natauri Jo | Director Director | May 13 | Sell | 30.68 | 2,626,771 | 80,589,334 | 24,807,518 | 05/13/21 |
Ohri Devashish | EVP, IMEA EVP, IMEA | Apr 13 | Option | 1.6 | 100,160 | 160,256 | 256,048 | 04/13/21 |
Vanderhaegen Frederic | EVP, Europe EVP, Europe | Apr 13 | Sell | 31.79 | 27,075 | 860,714 | 216,594 | 04/13/21 |
Wondrasch Michael | EVP & CIO EVP & CIO | Feb 08 | Option | 23.2 | 40,000 | 928,000 | 181,543 | 02/08/21 |
Wondrasch Michael | EVP & CIO EVP & CIO | Feb 08 | Sell | 29.77 | 49,468 | 1,472,662 | 141,543 | 02/08/21 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | Jan 13 | Option | 23.2 | 378,580 | 8,783,056 | 340,763 | 01/13/21 |
Brophy Gerard | EVP, Biopharma Produ.. EVP, Biopharma Production | Jan 13 | Sell | 30.06 | 378,580 | 11,380,115 | 178,515 | 01/13/21 |
Stubblefield Michael | President and CEO President and CEO | Dec 08 | Option | 1.6 | 1,090,970 | 1,745,552 | 1,945,717 | 12/08/20 |
Stubblefield Michael | President and CEO President and CEO | Dec 08 | Sell | 27.27 | 510,640 | 13,925,153 | 1,847,265 | 12/08/20 |
Natauri Jo | Director Director | Nov 12 | Buy | 17.15 | 15,199 | 260,663 | 58,861,148 | 11/12/20 |
Natauri Jo | Director Director | Nov 12 | Sell | 17.18 | 39,118 | 672,047 | 58,861,086 | 11/12/20 |
Ohri Devashish | EVP, IMEA EVP, IMEA | Oct 07 | Option | 1.6 | 103,440 | 165,504 | 201,671 | 10/07/20 |
Ohri Devashish | EVP, IMEA EVP, IMEA | Oct 07 | Sell | 23.45 | 103,440 | 2,425,668 | 151,671 | 10/07/20 |